Dr. Sasine on New Developments With CAR T-Cell Therapy

Video

Joshua P. Sasine, MD, PhD, clinical instructor of medicine, hematologist, and oncologist, University of California, Los Angeles, discusses new developments with CAR T-cell therapy.

Joshua P. Sasine, MD, PhD, clinical instructor of medicine, hematologist, and oncologist, University of California, Los Angeles, discusses new developments with CAR T-cell therapy.

Follow-up data from the initial trials of CAR T-cell therapy continue to show benefit with this approach. Moreover, providers have become more accustomed to how to use these therapies. In doing so, they have learned how to make these products safer and predict which patients are most likely to benefit from them. Such strategies include inhibiting cytokines that have a direct implication on the neurotoxicity of the CAR T cells, says Sasine. Another approach is bispecific CAR T cells, which are designed to eradicate one of the escape mechanisms that cancer cells have to avoid CAR T cell recognition.

It’s difficult to predict the likelihood of response to CAR T-cell therapy on an individualized level. However, the field is beginning to understand that there are certain cytokine profiles both before and after CAR T cells are administered that are associated with durable remissions. Moreover, there are certain pre-therapeutic indicators of response, including the depth of conditioning for CAR T cells. Notably, the depth of lymphodepletion can be modified, whereas other factors are merely predictive, concludes Sasine.

Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
© 2025 MJH Life Sciences

All rights reserved.